Latest Breaking News On - Prnewswire akeso - Page 1 : comparemela.com

The promising results of a phase II clinical study for Akeso s Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Canc

The promising results of a phase II clinical study for Akeso s Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Canc
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesPrnewswire akesoChina national medical products administrationAmerican society of clinical oncologyClinical cancer researchAmerican association for cancer researchAkeso incContact akeso business developmentAmerican associationCancer researchClinical oncologySummit therapeuticsMain boardStock exchangeAkeso public relations

Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023

/PRNewswire/ Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in.

United statesHong kongPrnewswire akesoAmerican society of hematologyAkeso incAmerican societyInvestigational new drugSummit therapeuticsMain boardStock exchangeMedical pharmaceuticalsHealth care amp hospitalsClinical trials amp medical discoveries

Akeso s Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric C

Akeso s Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric C
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongYu xiaPrnewswire akesoData monitoring committeeChina national medical products administrationAkeso incIndependent data monitoring committeeAnalysis highlightNational medical products administrationSummit therapeuticsMain boardStock exchangeAkeso public relations

Ivonescimab s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironment with Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in vitro HONG KONG, Nov. 2, 2023 /PRNewswire/ Akeso (9926.HK) today announced that its collaboration and licensing.

Hong kongSan diegoUnited statesPrnewswire akesoBinding of ivonescimab enables higher avidityAmerican association for cancer researchChina national medical products administrationAkeso incNational cancer instituteSummit therapeutics incContact akeso business developmentEuropean organization for researchSimultaneous presenceIvonescimab enables higher avidityTumor microenvironmentIncreased binding affinity

Phase 1a/1b Study Results of Akeso s PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy

Phase 1a/1b Study Results of Akeso s PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongPrnewswire akesoChina national medical products administrationAkeso incCell reports medicineSummit therapeuticsMain boardStock exchange